Neovacs' anti-TNF kinoid candidate nears critical clinical milestone
This article was originally published in Scrip
Executive Summary
The French biotechnology company Neovacs has reported positive data from a Phase IIa trial with its TNF-Kinoid product candidate in patients with rheumatoid arthritis (RA) who have become resistant to anti-TNF biologics, including anti-TNF monoclonal antibodies.